The Thermo Scientific™ CB Omni Agile online elemental analyzer provides unprecendented flexibility that provides various configurations to suit various applications while providing industry leading performance and analysis of the entire material stream. It allows you to blend, sort and monitor product quality of your materials in real-time which leads to reduced process upsets and increased throughput.
This allows you to forget about the need for continuous sampling!
The CB Omni Agile integrates into a material conveyor and provides a minute-by-minute elemental analysis of raw materials. Rely on accurate means for process control to achieve consistent stockpile and raw mix chemistry thus minimizing cost and improving process efficiency.
In this first in a series of four articles, ACROBiosystems review what they know about SARS-CoV-2 and COVID-19, the developments in fighting the pandemic and the threat of emerging variants.
Innovation and the Mastery of Core Technologies are the Keys for the Success of Bio-Pharmaceutical Enterprises
At the beginning of 2020, when COVID-19 broke out unexpectedly and viciously, top research institutions and enterprises in China responded quickly, and the virus antibody R&D team of Sino Biological Inc. was one of them. After receiving the task, the R&D team from Sino Biological started to invest themselves into this task without any delay and completed the expressions of important target antigen protein S-RBD of SARS-CoV-2 successfully within only 11 days, and developed industrial-grade core antigen protein reagents; also, it supported Wondfo to complete the marketing of the first batch of SARS-CoV-2 diagnostic products on February 22.
Research and Development Progress of a SARS-CoV-2 Neutralizing Antibody
It has been one year since the outbreak of COVID-19, but there is still an increasing number of confirmed cases. The epidemic situation is still challenged all over the world. The effective drug remains to be the key factor for keeping the epidemic in check and reducing mortality.
At present, the most effective treatment for COVID-19 is the plasma from convalescent patients, and its active ingredient is the neutralizing antibodies. The much anticipated COVID-19 vaccines also depend on the neutralizing antibodies produced by vaccines to achieve the protective effect.
The antiviral mechanism of SARS-CoV-2 neutralizing antibody